Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

XYL

Xylem Inc. Reports Strong Q3 2025 Growth

Xylem Inc. has reported its third-quarter 2025 results, showcasing impressive growth and performance. The company's revenue stood at $2.3 billion, marking an 8% increase on a reported basis and a 7% organic growth. Earnings per share (EPS) saw a 4% increase on a reported basis, amounting to $0.93, and a substantial 23% surge on an adjusted basis, reaching $1.37.

Net income attributable to Xylem for the quarter was $227 million, equivalent to $0.93 per share. However, the net income margin experienced a decline of 30 basis points, settling at 10.0 percent. On an adjusted basis, the net income was $333 million, or $1.37 per share, excluding specific impacts.

The company's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin saw a significant year-over-year increase of 200 basis points, reaching 23.2 percent. This exceptional margin expansion was attributed to productivity savings, strong price realization, and volume growth, surpassing the impact of inflation, investments, and mix.

Looking ahead, Xylem has raised its full-year 2025 revenue guidance to approximately $9.0 billion, reflecting a 5 to 6 percent increase on a reported basis and a 4 to 5 percent rise on an organic basis. Additionally, the adjusted EBITDA margin is expected to be around 22.0 to 22.3 percent, indicating an increase of 140 to 170 basis points from the previous year.

The company has also adjusted its full-year adjusted earnings per share to $5.03 to $5.08, up from the previous guidance of $4.70 to $4.85. Xylem's solid performance and confidence in its long-term financial framework indicate a positive trajectory for sustainable growth and value creation.

Following these announcements, the company's shares moved 0.78%, and are now trading at a price of $149.40. For the full picture, make sure to review Xylem's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS